Skip to content

A Randomized Trial of Behavioral Modification Program for Mothers of Children with Atopic Dermatitis

A Randomized Trial of Behavioral Modification Program for Mothers of Children with Atopic Dermatitis - A Randomized Trial of Behavioral Modification Program for Mothers of Children with Atopic Dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000794
Enrollment
100
Registered
2007-08-08
Start date
2007-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with Atopic Dermatitis

Interventions

Behavial Modification Program (One night hands-on hospital stay, self monitored skin-care according to skin-care table AND monthly feedback sessions by specialized nurse upto three months.) Standard

Sponsors

Gunma Prefectural College of Health Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Moderate or severe eczema according to Japanese Dermatology Association guideline.

Exclusion criteria

Exclusion criteria: 1) Need emergency addmission. 2) Under psychological therapy (either mother or child). 3) Serious co-mobidity which may interfare atopic dermatitis. 4) Cannot afford one-night hospital stay. 5) Parents are not involved. 6) In-charge doctor judges.

Design outcomes

Primary

MeasureTime frame
SCORAD at baseline, three and six month later

Secondary

MeasureTime frame
DFI (Family Impact of Childhood Eczema Questionnaire) QPCAD (Quality of Life in Primary Caregivers of children with Atopic Dermatitis) STAI (State Trait Anxiety Inventory) Ammount of steroid ointment prescribed after three and six months

Countries

Japan

Contacts

Public ContactMasaki Futamura

Aichi Children's Health and Medical Center Department of Allergy

m.futamura@mbe.ocn.ne.jp0562-43-0500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026